The upward revision of revenue projections for ZTALMY by Marinus Pharmaceuticals suggests a stronger than expected market acceptance and sales performance. This positive adjustment is likely to be viewed favorably by investors, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.